Nabriva Therapeutics (NASDAQ:NBRV) Raised to “Buy” at Zacks Investment Research
Zacks Investment Research upgraded shares of Nabriva Therapeutics (NASDAQ:NBRV) from a hold rating to a buy rating in a research note published on Tuesday, Zacks.com reports. Zacks Investment Research currently has $1.50 price target on the biotechnology company’s stock.
According to Zacks, “Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics’ medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics’ lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP). “
Several other brokerages have also recently weighed in on NBRV. Needham & Company LLC restated a buy rating on shares of Nabriva Therapeutics in a report on Wednesday, November 13th. BidaskClub downgraded shares of Nabriva Therapeutics from a sell rating to a strong sell rating in a research note on Tuesday, December 24th. Wedbush reiterated an outperform rating and issued a $7.00 target price on shares of Nabriva Therapeutics in a research note on Friday, November 15th. Finally, ValuEngine upgraded shares of Nabriva Therapeutics from a hold rating to a buy rating in a research note on Saturday, January 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $6.64.
Nabriva Therapeutics (NASDAQ:NBRV) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.04. The company had revenue of $6.92 million during the quarter, compared to analysts’ expectations of $1.23 million. Nabriva Therapeutics had a negative return on equity of 171.36% and a negative net margin of 910.45%. Sell-side analysts expect that Nabriva Therapeutics will post -1.14 earnings per share for the current fiscal year.
A number of hedge funds have recently modified their holdings of NBRV. Woodard & Co. Asset Management Group Inc. ADV acquired a new stake in Nabriva Therapeutics during the third quarter worth approximately $40,000. Sterling Investment Advisors Ltd. lifted its position in Nabriva Therapeutics by 100.0% during the third quarter. Sterling Investment Advisors Ltd. now owns 20,000 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 10,000 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in Nabriva Therapeutics by 1,616.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 35,771 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 33,687 shares during the last quarter. Raymond James & Associates acquired a new stake in Nabriva Therapeutics during the fourth quarter worth approximately $52,000. Finally, State Street Corp acquired a new stake in Nabriva Therapeutics during the third quarter worth approximately $65,000. Hedge funds and other institutional investors own 2.76% of the company’s stock.
Nabriva Therapeutics Company Profile
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
Read More: What is a capital gain?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.